Perimeter Medical Imaging AI Hosts Two Poster Presentations at the College of American Pathologists 2022 Annual Meeting
12 Octubre 2022 - 3:30PM
Business Wire
Research provides validation of wide-field
Optical Coherence Tomography (OCT) for microstructural analysis of
tissue from multiple organs and tissue types
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF)
(FSE:4PC) – a medical technology company driven to transform cancer
surgery with ultra-high-resolution, real-time, advanced imaging
tools to address high unmet medical needs – announced two poster
presentations at the Annual Meeting of the College of American
Pathologists 2022 (CAP22), which took place October 8 to 11, 2022
in New Orleans, LA. The research presented validates the potential
use of Perimeter S-Series OCT to intraoperatively image specimens
across a variety of tissue types, such as breast, thyroid, kidney,
liver, lung, colon, heart, pancreas, spleen, and adrenal
glands:
- Validation of Wide-Field Optical Coherence Tomography for
Microstructural Analysis of Tissue From Multiple Organs (Poster No.
108)
- Intraoperative Use of Wide-Field Optical Coherence Tomography
to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx
(Poster No. 170)
Andrew Berkeley, Perimeter’s Co-founder stated, “We were excited
to present to leading pathologists at CAP22 with data that support
the potential use of Perimeter’s OCT medical imaging technology
across several tissue types, including the analysis of margins in
head and neck surgery. This research helps demonstrate that
Perimeter S-Series has the potential to be used in a variety of
settings to help ‘bridge the gap’ between the surgeon’s need for
immediate ‘real time’ info in the operating room with images that
correlate to histological results, with a process that does not
interfere with surgical procedures or final pathology.”
About Perimeter Medical Imaging AI, Inc. Based in
Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI
(TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company
driven to transform cancer surgery with ultra-high-resolution,
real-time, advanced imaging tools to address areas of high unmet
medical need. Available across the U.S., our FDA-cleared Perimeter
S-Series OCT system provides real-time, cross-sectional
visualization of excised tissues at the cellular level, with 10x
greater image resolution than X-ray and ultrasound, and 100x
greater than MRI. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the Cancer
Prevention and Research Institute of Texas. The company’s ticker
symbol “PINK” is a reference to the pink ribbons displayed during
Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; Perimeter’s expected development activities and the
expected details regarding Perimeter’s ongoing clinical trials are
forward-looking information. Forward-looking statements should not
be read as guarantees of future performance or results, and will
not necessarily be accurate indications of whether, or the times at
or by which, any particular result will be achieved. No assurance
can be given that any events anticipated by the forward-looking
information will transpire or occur. Forward-looking information is
based on information available at the time and/or management’s
good-faith belief with respect to future events and are subject to
known or unknown risks, uncertainties, assumptions, and other
unpredictable factors, many of which are beyond Perimeter’s
control. Such forward-looking statements reflect Perimeter’s
current view with respect to future events, but are inherently
subject to significant medical, scientific, business, economic,
competitive, political, and social uncertainties and contingencies.
In making forward-looking statements, Perimeter may make various
material assumptions, including but not limited to (i) the accuracy
of Perimeter’s financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter’s Management Discussion and Analysis for the year
ended December 31, 2021, which is available on Perimeter’s SEDAR
profile at www.sedar.com, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221012006049/en/
Chris Scott Chief Financial Officer Perimeter Medical Imaging
AI, Inc. Investors: investors@perimetermed.com Toll-free:
888-988-7465 (PINK)
Jodi Regts Corporate Communications Perimeter Medical Imaging
AI, Inc. Media: media@perimetermed.com Mobile: 469-743-1834
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025